Boston Scientific Announces $1.0B Share Repurchase Program

Boston Scientific Corporation's BSX Board of Directors has approved a new program authorizing the repurchase of up to $1.0 billion of its common stock and re-approving the approximately 37 million shares remaining under an existing share repurchase program. "This repurchase program reflects our confidence in the strength of the Company's long-term business prospects, earnings growth potential and our ability to generate strong cash flow," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "Having reduced our gross debt to $4.2 billion, which is consistent with our targeted capital structure, we believe this new program provides us with added flexibility in our commitment to delivering value to shareholders." Any share repurchases are at the Company's discretion, subject to applicable law, market conditions, stock price and other factors.